ResearcherBrooke Army Medical CenterActive in the last 2 years
Phillip M. Kemp Bohan
Matched on ORCID iD 0000-0003-1240-3889; OpenAlex author ID A5027659488. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2022: 1 paper · 2023: 3 papers · 2024: 1 paper
Papers 5
- Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. Co-author DOI 10.1002/jso.27466↗
- Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12908-z↗
- ASO Author Reflections: The Complexity of the Volume-Outcome Relationship in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12920-3↗
- Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-023-13758-z↗
- Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. First author DOI 10.1245/s10434-022-11800-0↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniel William Nelson · 5 shared papers, 2022–2024 · strength 1.07
- Paper ASO Author Reflections: The Complexity of the Volume-Outcome Relationship in Pancreatic Cancer. DOI 10.1245/s10434-022-12920-3↗
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Alexandra M. Adams · 4 shared papers, 2022–2024 · strength 0.69
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Elizabeth L. Carpenter · 4 shared papers, 2022–2024 · strength 0.69
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Timothy J. Vreeland · 4 shared papers, 2022–2024 · strength 0.69
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Holly V. Spitzer · 2 shared papers, 2023 · strength 0.37
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Robert Connor Chick · 2 shared papers, 2022–2024 · strength 0.31
- Patrick M. McCarthy · 2 shared papers, 2022–2024 · strength 0.31
- Anne E. O’Shea · 2 shared papers, 2022–2024 · strength 0.31
- Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.18
- Ching-Wei David Tzeng · 1 shared paper, 2023 · strength 0.18
- Franklin A. Valdera · 1 shared paper, 2024 · strength 0.17
- Robert W. Krell · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.